Histone Demethylases

Histone demethylase inhibitors block the enzymes that remove methyl groups from lysine residues on histones. Lysine-specific demethylase 1 (LSD1) is a flavin-dependent amine oxidase that demethylates mono- and dimethylated lysine 4 of histone H3 (H3K4). The larger Jumonji C (JmjC) domain family uses iron and 2-oxoglutarate as cofactors, and some members also remove trimethyl marks. SP2509 and GSK2879552 are inhibitors of LSD1 used in chromatin and differentiation studies. GSK J1 targets two demethylases of lysine 27 on histone H3 (H3K27), Jumonji domain-containing protein 3 (JMJD3) and ubiquitously transcribed X-chromosome tetratricopeptide repeat protein (UTX). GSK-J4 is its cell-permeable ester, used for studies in intact cells. JIB-04 acts on several JmjC demethylases, and YUKA1 inhibits lysine-specific demethylase 5A (KDM5A).

Items 101-125 of 170

  • MC2652
    Cat. No.
    A29287

    MC2652

    MC2652 is a potent inhibitor of the lysine-specific demethylase 1 (LSD1). It exhibits significant inhibitory effects in MV4-11 and NB4 leukemia cells, indicating strong potential for hematological research. Additionally, MC2652 demonstrates antiproliferative activity against prostate cancer LNCaP cells, making it a valuable tool for exploring therapeutic strategies in oncology.

    Out of stock

    All 3 sizes
  • GSK-J5 hydrochloride
    Cat. No.
    A29288

    GSK-J5 hydrochloride

    GSK-J5 hydrochloride is a stable isomer of GSK-J4, serving as a negative control in glycosylation research. This cell-permeable ester derivative is characterized by its inactivity compared to its active counterparts. GSK-J5 hydrochloride is primarily utilized in experiments to differentiate specific biological effects and outcomes associated with GSK J4, aiding in the elucidation of complex cellular mechanisms.

    5 mg
    $215.00
    10 mg
    $380.00
    All 3 sizes
  • FY-21
    Cat. No.
    A29289

    FY-21

    FY-21 is a selective inhibitor of lysine-specific demethylase 1 (LSD1), exhibiting an IC50 of 340 nM. This compound demonstrates significant anti-proliferative effects and inhibits colony formation in cancer cells. Additionally, FY-21 enhances p53 expression while down-regulating HOXA9 and MEIS1, contributing to its potential in inducing differentiation in leukemia cells, thereby providing a promising avenue for antitumor research applications.

    Out of stock

    All 3 sizes
  • KDM4-IN-4
    Cat. No.
    A29290

    KDM4-IN-4

    KDM4-IN-4 is a potent inhibitor of histone lysine demethylase 4 (KDM4), specifically targeting the Tudor domain of KDM4A with a binding affinity of approximately 80 µM. This compound demonstrates the ability to inhibit the interaction of H3K4Me3 with the Tudor domain in cellular contexts, exhibiting an EC50 value of 105 µM. KDM4-IN-4 is utilized in anticancer research to explore its role in epigenetic regulation and potential therapeutic applications.

    1 mg
    $235.00
    5 mg
    $590.00
    All 5 sizes
  • LSD1-IN-34
    Cat. No.
    A29291

    LSD1-IN-34

    LSD1-IN-34 is a potent inhibitor of Lysine-specific demethylase 1 (LSD1) and monoamine oxidase A (MAO). It demonstrates IC50 values of 4.51 nM for LSD1 and 18.46 nM for MAO A, effectively blocking the activation of neonatal rat myocardial fibroblasts (NRCFs) induced by Ang II, with minimal toxicity at 20 μM. Furthermore, LSD1-IN-34 disrupts the TGFβ/Smad signaling pathway, providing therapeutic potential in ameliorating heart failure in mouse models. The compound also shows favorable pharmacokinetic properties in rats, supporting its use in cardiovascular research.

    Out of stock

    All 3 sizes
  • LSD1-IN-27
    Cat. No.
    A29292

    LSD1-IN-27

    LSD1-IN-27 is a potent inhibitor of the lysine-specific demethylase 1 (LSD1), exhibiting an IC50 of 13 nM. This compound effectively inhibits the stemness and migratory capacity of gastric cancer cells while decreasing PD-L1 expression in BGC-823 and MFC cell lines. Additionally, LSD1-IN-27 has been shown to enhance T cell immune responses in the context of gastric cancer, making it a valuable tool for research in cancer immunotherapy and cellular differentiation studies.

    5 mg
    $375.00
    10 mg
    $545.00
    All 3 sizes
  • LSD1/EGFR-IN-1
    Cat. No.
    A29293

    LSD1/EGFR-IN-1

    LSD1/EGFR-IN-1 is a potent inhibitor of lysine-specific demethylase 1 (LSD1) and several mutant forms of the epidermal growth factor receptor (EGFR), specifically EGFRT790M/L858R and EGFRL858R/T790M/C797S, exhibiting IC50 values of 6.24 μM, 2.06 μM, and 5.01 μM, respectively. This compound is significant for cancer research, particularly in studies focusing on targeted therapies and resistance mechanisms associated with EGFR mutations. Its application in preclinical models can aid in the understanding of tumorigenesis and the efficacy of combination therapies.

    Out of stock

    All 3 sizes
  • HSP90/LSD1-IN-1
    Cat. No.
    A29294

    HSP90/LSD1-IN-1

    HSP90/LSD1-IN-1 is a dual inhibitor targeting HSP90 and LSD1, effectively disrupting their interaction and function. This compound demonstrates significant antiproliferative activity in prostate cancer cell lines, exhibiting GI50 values of 0.24 μM for PC-3 and 0.30 μM for DU145. It is a valuable tool for research into therapeutic strategies against prostate cancer and the role of chaperone proteins and histone demethylases in tumor biology.

    Out of stock

    All 3 sizes
  • YU185530
    Cat. No.
    A29295

    YU185530

    YU185530 is a selective inhibitor of JARID1B, a histone demethylase involved in the regulation of gene expression. It has demonstrated biological activity in modulating epigenetic landscapes associated with cancer progression. This compound is primarily utilized in cancer research to explore the therapeutic potential of targeting JARID1B in various malignancies.

    Out of stock

    All 3 sizes
  • DDP-38003
    Cat. No.
    A29296

    DDP-38003

    DDP-38003 is a potent inhibitor of KDM1A/LSD1, with an IC50 value measured at 84 nM. This compound demonstrates significant anticancer activity, particularly against promyelocytic leukemia cells. DDP-38003 is suitable for research applications focused on gene regulation, epigenetic modulation, and cancer therapeutics.

    Out of stock

    All 3 sizes
  • LSD1-UM-109
    Cat. No.
    A29297

    LSD1-UM-109

    LSD1-UM-109 is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), exhibiting an IC50 of 3.1 nM. It demonstrates significant antiproliferative activity, with IC50 values of 0.6 nM in the MV4;11 acute leukemia cell line and 1.1 nM in the H1417 small-cell lung cancer cell line. This compound is valuable for research into cancer biology and the epigenetic regulation of gene expression, making it a crucial tool for studying LSD1’s role in various malignancies.

    25 mg
    $1,530.00
    50 mg
    $1,950.00
    All 3 sizes
  • LSD1-IN-41
    Cat. No.
    A29299

    LSD1-IN-41

    LSD1-IN-41 is a potent and selective inhibitor of lysine-specific demethylase 1 (LSD1). It demonstrates significant biological activity in cancer research, particularly in the context of diffuse intrinsic pontine glioma (DIPG), especially when used in combination with histone deacetylase (HDAC) inhibitors. This compound serves as a valuable tool for investigating epigenetic regulation and therapeutic strategies in cancer treatment.

    Out of stock

    All 3 sizes
  • KDM4C-IN-2
    Cat. No.
    A29300

    KDM4C-IN-2

    KDM4C-IN-2 is a selective inhibitor of the histone lysine demethylase KDM4C, exhibiting an IC50 value of 147 μM and a Ki of 51 μM. This compound plays a crucial role in regulating histone methylation, making it valuable for cancer research, particularly in the study of prostate and breast cancer. KDM4C-IN-2 can aid in understanding the epigenetic mechanisms underlying tumorigenesis and potential therapeutic strategies.

    25 mg
    $20.00
    50 mg
    $25.00
    All 6 sizes
  • INCB059872 tosylate
    Cat. No.
    A29301

    INCB059872 tosylate

    INCB059872 tosylate is a potent, selective inhibitor of lysine-specific demethylase 1 (LSD1). By binding to and inhibiting LSD1, this compound enhances H3K4 methylation, which increases the expression of tumor suppressor genes. Additionally, the inhibition of LSD1 promotes H3K9 methylation, leading to a decrease in the transcription of genes associated with tumor promotion. Its properties make INCB059872 tosylate valuable for research on epigenetic regulation and cancer therapy.

    Out of stock

    All 3 sizes
  • S1427
    Cat. No.
    A29303

    S1427

    S1427 is a tranylcypromine-derived inhibitor of lysine-specific demethylase 1 (LSD1) with an IC50 of 390 nM and a Ki of 80 nM. This compound demonstrates selective inhibition of the hERG channel and displays favorable microsomal stability profiles. S1427 has been shown to partially reduce the proliferation of cancer cells, making it a valuable tool for research in cancer biology and epigenetic regulation.

    Out of stock

    All 3 sizes
  • GSK 690
    Cat. No.
    A29304

    GSK 690

    GSK 690 is a reversible inhibitor of lysine-specific demethylase 1 (LSD1), showcasing a Kd value of 9 nM and a biochemical IC50 of 37 nM. This compound serves as a valuable tool for studying histone modifications and gene regulation. Its inhibitory properties make it a significant reagent in epigenetic research and the exploration of cancer biology.

    1 mg
    $235.00
    5 mg
    $590.00
    All 5 sizes
  • LSD1-IN-23
    Cat. No.
    A29305

    LSD1-IN-23

    LSD1-IN-23 is a mixed inhibitor of lysine-specific demethylase 1 (LSD1), exhibiting both competitive and non-competitive inhibition patterns. With an IC50 value of 0.58 μM, it effectively inhibits LSD1 activity, making it a valuable tool for investigating the role of LSD1 in neuroblastoma (NB) research and related studies on cancer epigenetics.

    Out of stock

    All 3 sizes
  • LSD1/2-IN-4
    Cat. No.
    A29306

    LSD1/2-IN-4

    LSD1/2-IN-4 is an inhibitor of lysine-specific demethylase 1 (LSD1) and lysine-specific demethylase 2 (LSD2), exhibiting Ki values of 0.11 μM and 130 μM, respectively. This compound selectively inhibits demethylase activity, making it valuable for studying epigenetic regulation in various biological processes. LSD1/2-IN-4 has potential applications in cancer research, including investigations into T-cell acute lymphoblastic leukemia (TALL), providing insights into therapeutic strategies targeting demethylase pathways.

    Out of stock

    All 3 sizes
  • NCL1
    Cat. No.
    A29307

    NCL1

    NCL1 is a selective inhibitor of Lysine-specific demethylase 1 (LSD1), a pivotal enzyme in the regulation of gene expression through histone modification. With an IC50 value of 2.5 μM for LSD1 and 26 μM for LSD2, NCL1 demonstrates a preferential inhibition of LSD1 over its close homolog. This compound is primarily utilized in research applications related to epigenetics, cancer biology, and neurodegenerative disorders, facilitating investigations into the molecular mechanisms of gene regulation.

    Out of stock

    All 3 sizes
  • cis-4-Br-2,5-F2-PCPA
    Cat. No.
    A29308

    cis-4-Br-2,5-F2-PCPA

    Synonyms: S1024

    cis-4-Br-2,5-F2-PCPA is a selective inhibitor of lysine-specific demethylase 1 (LSD1), demonstrating a Ki value of 94 nM for LSD1 compared to 8.4 μM for LSD2. This compound effectively inhibits LSD1 activity, resulting in reduced proliferation of cancer stem cells by increasing the levels of dimethylated histone H3 at lysine 4 (H3K4) in CCRF-CEM cells. Its selective action makes cis-4-Br-2,5-F2-PCPA a valuable tool for research on epigenetic regulation and cancer biology.

    Out of stock

    All 3 sizes
  • KDM5-C49
    Cat. No.
    A29309

    KDM5-C49

    Synonyms: KDOAM-20

    KDM5-C49 is a potent and selective inhibitor of KDM5 demethylases, exhibiting IC50 values of 40 nM, 160 nM, and 100 nM for KDM5A, KDM5B, and KDM5C, respectively. This compound plays a critical role in epigenetic research, particularly in the study of cancer biology. It provides valuable insights into the mechanisms of gene regulation and the potential therapeutic strategies targeting KDM5 demethylases in cancer treatment.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • LSD1-IN-48
    Cat. No.
    A29310

    LSD1-IN-48

    LSD1-IN-48 is a selective inhibitor of lysine-specific demethylase 1 (LSD1), featuring a tranylcypromine-pyrimidine structure with a human IC50 of 7.87 nM. This compound enhances histone methylation levels of H3K4me1 and H3K4me2, promoting apoptosis in cancer cells. Additionally, LSD1-IN-48 upregulates CD86 and downregulates SOX2 and CD44, leading to reduced cell proliferation. It is particularly useful for research into acute myeloid leukemia.

    Out of stock

    All 3 sizes
  • LSD1-IN-35
    Cat. No.
    A29311

    LSD1-IN-35

    LSD1-IN-35 is a selective inhibitor of lysine-specific demethylase 1 (LSD1) with an IC50 of 108 nM. By inhibiting the demethylation of H3K4me1/2, LSD1-IN-35 acts as an immunomodulator, enhancing the response of gastric cancer cells to T-cell-mediated cytotoxicity. This compound decreases PD-L1 expression, thereby mitigating the PD-1/PD-L1 interaction, which is critical in tumor immune evasion. Its potential applications include cancer research and the study of immune regulation in tumor microenvironments.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • GSK-J2 sodium
    Cat. No.
    A29312

    GSK-J2 sodium

    GSK-J2 sodium is the sodium form of GSK-J2, an inactive isomer of the active compound GSK-J1. While GSK-J1 functions as a potent inhibitor of the H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A, GSK-J2 sodium does not exhibit specific biological activity. This reagent may be utilized in studies focused on differentiating between active and inactive isomers in the context of epigenetic regulation and demethylase inhibition.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • LSD1-IN-18
    Cat. No.
    A29313

    LSD1-IN-18

    LSD1-IN-18 is a selective, non-covalent inhibitor of LSD1, exhibiting a Ki of 0.156 μM and a KD of 0.075 μM. It demonstrates significant antiproliferative effects in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with calculated IC50 values of 0.16 μM and 0.21 μM, respectively, after 72 hours of treatment. This compound provides a valuable tool for investigating the role of LSD1 in cancer biology and therapeutic applications.

    Out of stock

    All 3 sizes

Items 101-125 of 170

Added to your cart

View Cart Checkout

    Loading...